Pendulum Therapeutics Raises $54 million
Gut health biotech company Pendulum Therapeutics recently announced a $54 million investment led by Meritech Capital with participation from existing investors including Sequoia Capital, True Ventures and Khosla Ventures.
The Series C round nearly doubled the entirety of Pendulum’s previous raises, bringing the total venture capital raised to $111 million.
As lead investor, Meritech General Partner Craig Sherman will take a seat on the Pendulum Board of Directors alongside Roelof Botha, a partner at Sequoia, and Adam D’Augelli, a partner at True Ventures.
“We think Pendulum is a next generation pharma company doing next generation gene sequencing,” said Sherman.